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Abstract
Background The increasing problem of multidrug-resistant
Gram-negative bacteria causing severe infections and the
shortage of new antibiotics to combat them has led to the re-
evaluation of polymyxins. These antibiotics were discovered
from different species of Bacillus polymyxa in 1947; only two of
them, polymyxin B and E (colistin), have been used in clinical
practice. Their effectiveness in the treatment of infections due to
susceptible Gram-negative bacteria, including Pseudomonas
aeruginosa and Acinetobacter baumannii, has not been
generally questioned. However, their use was abandoned,
except in patients with cystic fibrosis, because of concerns
related to toxicity.
Methods We reviewed old and recent evidence regarding
polymyxin-induced toxicity by searching Pubmed (from 1950
until May 2005).
Results It was reported in the old literature that the use of
polymyxins was associated with considerable toxicity, mainly
nephrotoxicity and neurotoxicity, including neuromuscular
blockade. However, recent studies showed that the incidence of
nephrotoxicity is less common and severe compared to the old
studies. In addition, neurotoxic effects of polymyxins are usually
mild and resolve after prompt discontinuation of the antibiotics.
Furthermore, cases of neuromuscular blockade and apnea have
not been reported in the recent literature.
Conclusion New evidence shows that polymyxins have less
toxicity than previously reported. The avoidance of concurrent
administration of nephrotoxic and/or neurotoxic drugs, careful
dosing, as well as more meticulous management of fluid and
electrolyte abnormalities and use of critical care services may be
some of the reasons for the discrepancy between data reported
in the old and recent literature.
Introduction
Polymyxins were discovered in 1947 from different species of
Bacillus polymyxa [1,2]. Although the effectiveness of poly-
myxins against most Gram-negative bacteria, including Pseu-
domonas aeruginosa and Acinetobacter baumannii, has not
been questioned, early administration of polymyxins was asso-
ciated with reports of adverse renal and neurological effects in
a considerably large number of patients [3,4]. Thus, com-
pounds of this class of antibiotics were gradually withdrawn
from clinical practice as newer antibiotics with the same or
broader antibacterial spectra and reportedly lower toxicity
were introduced, except for patients with cystic fibrosis who
suffer from recurrent pulmonary infections due to multidrug-
resistant bacteria [5-7]. However, the emergence of Gram-
negative bacteria that are resistant to almost all classes of
available antibiotics except polymyxins, especially Pseu-
domonas aeruginosa and Acinetobacter baumannii strains,
and the shortage of new antibiotics with activity against them
has led to the re-use of polymyxins [8-12]. The objective of this
critical review of the old and recent literature is to elucidate the
incidence, mechanisms, prevention, and treatment of adverse
events of polymyxins, focusing on patients without cystic fibro-
sis.
This class of antibiotics consists of five chemically different
compounds, polymyxin A, B, C, D, and E (colistin). Only poly-
myxins B and E have been used in clinical practice. Colistin
consists of a cyclic heptapeptide and a tripeptide side-chain
acylated at the amino terminus by a fatty acid. The amino acid
components in the molecule of colistin are D-leucine, L-threo-
nine, and L-α-γ-diaminobutyric acid. Polymyxin B has the same
structure as colistin but contains D-phenylalanine instead of D-
leucine [13].
Commercially, colistin appears as colistin sulfate, which is
used orally for bowel decontamination and topically as a pow-Critical Care    Vol 10 No 1    Falagas and Kasiakou 
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der for skin infections, and as colistimethate sodium, which is
used parenterally and by inhalation. Colistimethate sodium has
been found to be less toxic and to have fewer undesirable side
effects than colistin, but is also less potent. Polymyxin B is
available for clinical use as polymyxin B sulfate and is used
parenterally, topically (ophthalmic and otic instillation), intrath-
ecally, by inhalation, and as an irrigation solution [14,15].
Several attempts to generate less toxic derivatives were made
[16]. Most of these derivatives lacked the fatty acid and/or the
diaminobutyric acid components of their original molecules.
Experimental studies demonstrated that these compounds
were much less toxic compared to the parent ones, but at the
same time they had considerably reduced antibacterial effect
[17,18].
Methods
Data for this review were obtained through literature searches
of publications included in PubMed from 1950 until May
2005, references cited in relevant articles, and the world-wide
web. The main search terms used in searches of literature
databases were 'colistin', 'polymyxin E', 'polymyxin B', 'adverse
effects', 'nephrotoxicity', 'colomycin', 'colimycin', 'neurotoxicity'
and 'toxicity'. Only English language papers were reviewed.
Results and discussion
In Tables 1 and 2 we summarize the available publications
reporting data regarding the incidence of toxicity, including
nephrotoxicity, neurotoxicity, and other adverse effects of pol-
ymyxins. Specifically, Tables 1 and 2 refer to old (from 1962 to
1977) and recent (from 1995 to 2005) articles, respectively,
reporting adverse effects of polymyxins in patients without
cystic fibrosis.
Nephrotoxicity
Incidence
Although most of the studies or case reports published until
1983 did not include the definitions of nephrotoxicity, early
reported experience with the use of polymyxins, mainly of col-
istin, revealed a high incidence of nephrotoxicity. The majority
of the studies in the older literature referred to intramuscular
administration of colistimethate sodium [4,19-25]. Notably,
the incidence of nephrotoxicity was 36% in a study of patients
with pre-existing acute or chronic renal disease and 20.2% in
another large study of 288 patients [4,25]. Additionally, in
three studies [26-28], intravenous colistimethate sodium was
given for the treatment of patients with Gram-negative bacte-
rial infections, including urinary tract infections, pneumonia,
and septicaemia. These studies included 48, 23, and 8
patients, respectively; 10.5% of patients had prolonged
increase of blood urea nitrogen levels (average increase of 50
mg/dl) [26], 26.1% of patients experienced renal impairment
during therapy [27], and 50% had a fall in creatinine clearance
(with a range of 16.5 to 38 ml/min) and an increase in serum
creatinine levels (with a range of 0.2 to 2 mg/dl) [28]. Another
interesting finding was the relatively high number of case
reports that were published in the old literature reporting
patients who experienced acute renal failure during treatment
with colistimethate sodium. A point that deserves to be
stressed, however, is that in most of these cases the total daily
dose of colistimethate sodium was considerably higher com-
pared to the currently recommended dose [3,29-34].
During the past seven years, colistimethate sodium has been
re-introduced to clinical practice for the treatment of multid-
rug-resistant bacterial infections, mainly in the intensive care
unit setting [9,10,12]. Data from recent studies do not corrob-
orate the previously reported high incidence of polymyxin
induced nephrotoxicity [11,35]. Although, the definition of
nephrotoxicity was not standardized between the studies, two
of them, which were conducted exclusively in intensive care
units and used colistimethate sodium, reported that the
observed nephrotoxicity was 14% [11] and 18.6% [12]. Nota-
bly, in one study that compared two therapeutic approaches –
intravenous colistimethate sodium versus intravenous imi-
penem/cilastatin for the management of patients with ventila-
tor-associated pneumonia due to Acinetobacter baumannii,
nephrotoxicity occurred in 24% and 42% of patients, respec-
tively [9]. Of note, polymyxin B was reported in the old litera-
ture to be associated with a relatively increased incidence of
toxicity compared to colistimethate sodium. However, these
data were not verified in two recent studies that showed that
the incidence of nephrotoxicity was 14% [36] and 10% [37]
among patients receiving polymyxin B therapy. Our experience
is similar to that of the investigators of the previous studies
[35,38].
Mechanisms
It has been suggested that the toxicity of polymyxins may be
partly due to their D-amino acid content and fatty acid compo-
nent. The proposed mechanism by which polymyxin B induces
nephrotoxic events is by increasing membrane permeability,
resulting in an increased influx of cations, anions, and water,
leading to cell swelling and lysis [39,40]. An experimental
study showed that colistin increased the transepithelial con-
ductance of the urinary bladder epithelium [41]. The magni-
tude of the conductance's increase was dependent on
concentration and length of exposure to polymyxins as well as
the divalent cation concentration. The basic molecular mecha-
nisms by which polymyxin B increases the transepithelial con-
ductance in the urinary tract has been proposed to be the
same as that of colistin [41]. Renal toxicity associated with the
use of polymyxins is considered to be dose-dependent.
Clinical manifestations
Renal insufficiency, manifested by an increase in serum creat-
inine levels and decrease in creatinine clearance, represents a
major adverse effect of the use of polymyxins. Occurrence of
haematuria, proteinuria, cylindruria, or oliguria may also be
associated with the administration of polymyxins. In addition,A
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Table 1
Old studies (from 1962 to 1977) reporting data on polymyxin-induced toxicity in patients without cystic fibrosis
Year [ref] Setting Medication used Number of 
patients
Demographics Dosage of colistin/duration Nephrotoxicity Neurotoxicity Other toxicities
1 1962 [26] Medical wards Colistimethate sodium (IV) 48 Adults: 150 mg q12 h Children: 
5 to 10 mg/kg/day. Duration: at 
least 10 days
12 pts had transient mild 
elevation of BUN (average 
increase 14 mg/dl) and returned 
to normal. 5 pts had prolonged 
elevation of BUN (average 
increase 50 mg/dl) and returned 
to normal
13/48 pts paresthesias; 3/48 
pts ataxia
3/48 pts pruritus. No drug fever, 
hepatic or bone marrow 
toxicity
2 1963 [19] Medical wards Colistimethate sodium (IM) 1 64 year old male 6.5 mg/kg/day (150 mg q8 h) 
for 12 days (he received 
concurrently kanamycin IM for 2 
days and after colistin therapy 
chloramphenicol)
BUN increased from normal 
baseline values to 44 mg/dl 
(drug was stopped). The BUN 
continued to rise and then 
began to return to normal. 
Postmortem examination of the 
kidney revealed findings 
compatible with drug induced 
nephrotoxicity
Possible hepatotoxicity
3 1963 [66] Medical and 
surgical wards
Colistimethate sodium (IM 
and topically)
62 Topically: 1% or 2% solution 
q4h or q12h. Duration (range): 2 
to 7 d Intramuscularly (range): 
150 to 300 mg/day. Duration 
(range): 1.5 to 19 d
Topically: no side effects Topically: no side effects 
Intramuscularly: 15/55 pts 
reported one or more of the 
following: lethargy, dizziness, 
nausea, confusion, slurred 
speech, numbness, 
paresthesias, pruritus, pain at 
the injection
Topically: no side effects
4 1963 [20] Medical wards Colistimethate sodium (IM) 11 Dosagea: 1.5 MIU q12h for a 
week and continued for a further 
week if the pt was improving (2 
pts received 2 MIU q8h for 5 
days and then 3 MIU q8h)
No renal toxicity 2 pts trigeminal paresthesia 1 pt developed follicular rash of 
the face
14 Dosage (range): 1 MIU q12h to 
1.5 MIU q8 h for 7 or more days
5 1964 [28] Medical wards Colistimethate sodium (IV) 8 Age (range): 25 to 69 
years
Dosage: 2 to 2.5 mg/kg q12 h. 
Duration (range): 8 to 14 days.
4/8 pts fall in creatinine 
clearance (range: 16.5 to 38 ml/
min) and increase in serum 
creatinine (range: 0.2 to 2 mg/
dl)
No neurotoxicity No pruritus
6 1964 [21] Children's hospital Colistimethate sodium (IM) 36 new-
borns
Age (range): 6 hours to 
12 days
Dosage (range): 2.5 to 5 mg/kg/
day in 2 to 4 doses. Total dose 
(range): 10 to 240 mg (1 new-
born (3.3 kg) received 160 mg 
of colistin (overdosage) in 7 
days)
16 pts had renal epithelial 
tubular cells on urinalyses; 14 
pts had urinary protein excretion
No neurotoxicity
7 1964 [22] Medical wards Colistimethate sodium (IM) 1 50 year old male Dosage: 300 mg/day for 5 days, 
then 200 mg/day for 4 days
Urinary retention, rise in blood 
urea nitrogen
Difficulty in breathing, 
dysphagia, generalized 
weakness, hallucinations, apnea 
requiring intubation
8 1965 [50] Medical wards Colistimethate sodium (IM) 1 66 year old female with 
azotemia
Dosage: 150 mg q 12 h for 8 
days. Cumulative dose: 2,550 
mg
7th day of colistin: circumoral 
paresthesias; 8th day: vomiting, 
difficulty in breathing, moving, 
speaking, and became apneic; 
10th day: grand mal seizures 
followed by transient right facial 
and arm weakness
9 1965 [24] Medical wards Colistimethate sodium (IM) 17 (19 
courses)
Age (range): 33 to 90 
years
Total cumulative dose (range): 
0.56 gr to 2.4 gr
8 pts dizziness – vertigo (1 pt 
discontinued), 5 pts oral 
paresthesias
3 pts pain at site of injection, 3 
pts nausea/vomiting, 2 pts 
pruritus/rashC
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10 1965 [23] Medical wards Colistimethate sodium (IM) 1 75 mg q12 h Episodes of ptosis, muscular 
weakness of the face and of the 
extremities
11 1965 [25] Medical wards 
(renal department)
Colistimethate sodium (IM) 25 12 males, 13 females. 
Age (range): 14 to 66 
years. All with impaired 
renal function
Dosage (range): 2 MIU to 4.4 
MIU/day. Duration (average): 8.5 
days
9/25 pts had an increase in 
plasma creatinine levels
12 1966 [46] Medical wards Colistimethate sodium (IM) 1 47 year old female 100 mg q8h Perioral paresthesia, numbness 
in the hands, weakness, ataxia, 
lightheadedness, shortness of 
breath, apnea
Nausea, itching of the face, 
hands, and arms (no visible 
rash)
13 1966 [67] Medical wards Colistimethate sodium (IM) 21 All had urinary tract 
abnormalities or had 
undergone 
prostatectomy
Dosage: 120 mg (1.5 MIU) q8h 
for 7 days
No constant effect on creatinine 
clearance was observed
14 1966 [43] Medical wards Colistimethate sodium (IM) 4 who 
developed 
acute renal 
failure
Age (range): 41 to 75 
years. All with pre-
existing renal disease
Dosage: 5 to 6.3 mg/kg/day. 
Duration (range): 3 to 12 days
Acute tubular failure (3 pts acute 
tubular necrosis, 1 pt recovered)
Retrosternal discomfort 1 pt
15 1966 [48] Medical wards Colistimethate sodium (IM) 1 48 year old female 75 mg q12h (she also received 
chloramphenicol 500 mg q6h 
po)
Diplopia and bilateral eye ptosis, 
weakness of neck flexion, 
difficulty in raising her arms
16 1966 [51] Department of 
anaesthesiology
Colistimethate sodium (IM) 1 49 year old female with 
nephrolithiasis
75 mg q12 h (she also received 
chloramphenicol 500 mg q4h 
po and sulfisoxazole 1 g q4h po)
Post-operative apnea
17 1967 [27] Medical and 
surgical wards
Colistimethate sodium (IV) 23 Males, moderately to 
severely ill
Dosage (range): 1.1 to 5 mg/kg/
day q12h for 6 to 7 days (in 2 
cases the treatment was 
discontinued after 2 and 3 days)
6/23 pts renal impairment; 7/23 
pts albuminuria
1 pt circumoral paresthesia 5/23 pts mild itching
18 1968 [44] Medical wards Colistimethate sodium (IV) 7 Age (range): 28 to 48 
years. 4 females, 3 
males; all had terminal 
and irreversible renal 
failure
2 to 3 mg/kg (1 dose) 2 pts mild dizziness and 
instability
19 1968 [56] Medical wards Colistin sulfate (PO) 93 (48 
cases E. 
coli and 45 
cases 
Shigella 
spp.)
E. coli : 100,000 IU/kg/day in 
adults and 150,000 IU/kg/day in 
children for 7 days Shigella: 
200,000 IU/kg/day in adults and 
300,000 IU/kg/day in children 
for 8 to 10 days
No toxic symptoms No toxic symptoms 1 pt generalized rash, 1 pt 
vomiting
20 1968 [49] Medical wards 
(respiratory care 
unit)
Colistimethate sodium (IM) 
and Polymyxin B (IM or IV)
11 Age (range): 36 to 74 
years. 4 females, 7 
males; all had acute or 
chronic renal disease
Dosage of colistimethate 
sodium (range): 100 to 400 mg/
day. Duration (range): 1 to 29 
doses or 1 to 15 days. Dosage 
of polymyxin B: 50 mg (1 dose) 
IM (1 pt) and 100 mg (1 dose) 
IV (1 pt)
All pts at their admission had 
apnea that recovered in all 
cases. Paresthesias 2 pts, 
diplopia 3 pts, difficulty in 
swallowing 3 pts, ptosis 2 pts, 
generalized weakness 3 pts, 
blurring of vision 1 pt, slurred 
speech 1 pt, lethargy 1 pt, coma 
1 pt
21 1969 [42] Medical wards Colistimethate sodium (IV) 1 14 year old male with 
acute leukemia
Dosage: 5 mg/kg/day for 5 
days, then increased to 7 mg/
kg/day on day 6, 10 mg/kg/day 
on day 7, and 17 mg/kg/day on 
day 9. Duration: 14 days
Acute tubular necrosis
22 1969 [29] Medical wards 
(pediatrics)
Colistimethate sodium (IM) 1 4 year old female with 
appendicitis
Dosage: 30 mg/kg q6h (total 
dose received 1,050 mg during 
42 h
Acute renal failure Neuromyal hyperactivity, seizure-
like episodes, uncoordination, 
disorientation, flaccid 
quadriplegia, respiratory arrest, 
apnea
Table 1 (Continued)
Old studies (from 1962 to 1977) reporting data on polymyxin-induced toxicity in patients without cystic fibrosisA
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23 1970 [4] Medical and 
surgical wards
Colistimethate sodium (IM) 288 (317 
courses)
205 courses received a total of 
<1 gr, 69 courses 1 to 2 gr, 43 
courses > 2 gr. All courses were 
administered IM q12 h
Total: 64/317 courses (renal 
insufficiency 63 pts, acute 
tubular necrosis 6 pts, hematuria 
1 pt)
Total: 23/317 courses 
(paresthesias 15 pts, respiratory 
insufficiency and apnea 6 pts, 
nausea and vomiting 4 pts, 
dizziness 3 pts, muscular 
weakness 2 pts, peripheral 
neuropathy, confusion, 
psychosis, convulsive seizure 1 
pt each)
Total allergic reactions: 7/317 
(drug fever 3 pts, eosinophilia 
2 pts, macular eruption 2 pts, 
urticarial eruption 1 pt)
24 1970 [68] Medical wards 
and ICU
Colistimethate sodium 
(aerosol)
20 Age (range): 23 to 81 
years
Group 1: 50 mg q8h for 7 days. 
Group 2: 100 mg q8h for 7 days
No toxic symptoms 1 pt experienced palpitations 
and a sensation of chest 
tightness (treatment was 
discontinued)
25 1970 [3] Department of 
pediatrics
Colistimethate sodium (IM) 1 Age: 10 months (male) 15 mg q6 h (2 doses) and then 
250 mg (38.5 mg/kg) (3 dose)
Acute renal failure No neurotoxicity
26 1970 [30] ICU, 
neurosurgical 
department
Colistimethate sodium (IV, 
IM, and aerosol)
14 Age (range): 31 to 71 
years
Mean duration: 9.7 days. 
Dosage: 26 MIU/day: 10 MIU 
IM, 10 MIU IV, and 6 MIU 
aerosol
In all pts a considerable fall in 
creatinine clearance and rises in 
blood urea and serum creatinine 
levels were observed. 5 pts 
developed acute tubular 
necrosis (histological 
confirmed). In 6 pts renal 
function returned to normal
27 1970 [69] Department of 
renal disease
Colistimethate sodium 
(route of administration not 
reported)
1 41 year old Duration: 7 days. Dose: 6.3 mg/
kg/day
Severe oliguric renal failure
28 1970 [31] Department of 
pediatrics
Colistimethate sodium (IM) 1 3 year old 150 mg q8h (she received 3 
injections)
No renal toxicity No neurotoxicity
29 1970 [32] Medical wards 
(urology 
department)
Colistimethate sodium (IM) 1 33 year old male with a 
solitary kidney
25 mg q6h for 5 days and 250 
mg q6h for 1 day
Increase in serum creatinine 
levels compared to baseline 
levels (1.1 mg/dl to 3 mg/dl) 
Returned to approximately 
normal values after 6 months
Muscular weakness, generalized 
paresthesias, speech 
disturbances, ptosis, hypotonia, 
areflexia, ataxia, difficulty in 
breathing
30 1971 [47] Department of 
neurology
Colistimethate sodium (IM) 1 70 year old male with 
myasthenia gravis
150 mg (one injection) 2 hours after the injection: 
muscular weakness; 30 minutes 
later he developed respiratory 
arrest
31 1971 [70] Department of 
respiratory 
diseases
Polymyxin B (aerosol) 2 Case 1: 51 year old 
female. Case 2: 57 
year old male
Case 1: 15 mg Case 2: 10 mg Case 1: pruritus, nausea, 
flashing, dyspnea Case 2: acute 
respiratory acidosis
32 1973 [33] Medical wards 
(Hemodialysis 
Centre)
Colistimethate sodium (IM) 2 Case 1: 16 year old 
female. Case 2: 23 
year old female
Case 1: 150 mg q6h 1st day, 
150 mg q4h 2nd day (20 mg/
kg/day) Case 2: 180, 240, 180, 
120 mg in divided doses on 1st, 
2nd, 3rd, 4th day, respectively
Both pts developed acute renal 
failure
Case 1: neuromuscular 
blockade that resulted in 
quadriplegia, apnea, cardiac 
arrest Case 2: circumoral – acral 
paresthesias
33 1974 [71] Medical wards Colistimethate sodium (IM) 1 66 year old male 6 MIU/day for 60 days No renal toxicity Total ophthalmoplegia, flaccid 
paralysis of both upper limbs, 
reduced speech fluency, 
difficulty in finding words, apathy
34 1977 [34] Department of 
pediatrics
Colistimethate sodium (IM) 1 5 year old male 200,000 IU/kg/day for 8 days Acute oliguric renal failure Muscular weakness, speech 
disturbances
a1 mg of colistimethate sodium is approximately equal to 12,500 IU. BUN, blood urea nitrogen; ICU, intensive care unit; IM, intramuscularly; IV, intravenously; MIU, million international units; po, 
per os; Pt(s), patient(s); ref, reference.
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acute tubular necrosis can also develop [14]. Histological find-
ings of colistin-induced renal damage usually involve focal
irregular dilatation of tubules, epithelial and polymorphonu-
clear cell cast formation, and degeneration and regeneration
of epithelial cells. In addition, separation of tubules by loose
collagenous tissue, suggestive of edema, has also been
reported. The basement membrane is usually intact, as well as
the glomeruli [19,42].
Risk factors
Nephrotoxicity resulting from the use of colistimethate sodium
appears to be less compared with that associated with poly-
myxin B. It is unclear whether there are independent factors
that predispose patients to the development of nephrotoxic
events. Children seem to experience less polymyxin-induced
toxicity, probably in part because prescription of polymyxins,
and generally all medications, is based on individual body
weight in this patient population [4]. Concomitant administra-
tion of potential nephrotoxic agents, such as diuretics and
some antimicrobial agents, increases the likelihood of devel-
opment of renal adverse effects [4,43].
Treatment
When primary signs of renal dysfunction are present, early dis-
continuation of polymyxins is necessary. Quick diuresis by
intravenously administered mannitol has also been proposed
to enhance renal clearance of the drug and thus to reduce
serum drug levels [32]. Meticulous supportive care, including
close monitoring of fluid intake and output, frequent determi-
nations of electrolytes, and appropriate management to main-
tain balance of fluids and electrolytes, is required when renal
adverse effects of polymyxin use are detected. The influence
of hemodialysis and peritoneal dialysis in decreasing serum
levels of polymyxins has not been clarified. Old reports sug-
gested that the amount of drug that is removed from blood by
these two methods is relatively small [44,45]. Patients that
underwent peritoneal dialysis lost approximately 1 mg of colis-
timethate sodium per hour [45]. Thus, in cases of polymyxin-
induced renal failure, both therapeutic approaches have been
used, not to decrease serum drug levels but in order to man-
age renal complications. Exchange transfusions have been
proposed as an effective method for the removal of polymyxins
[3].
Neurotoxicity
Incidence
The incidence of neurotoxicity related to the use of polymyxins
reported in the old literature was considerably less compared
to nephrotoxicity. Specifically, the most frequently experienced
neurological adverse effects were paresthesias that occurred
in approximately 27% and 7.3% of patients receiving intrave-
nous and intramuscular colistimethate sodium, respectively
[4,26]. Furthermore, at least eight cases were published
between 1964 and 1973 correlating the intramuscular admin-
istration of polymyxins with the development of episodes of
respiratory apnea [22,33,46-51]. However, recently per-
formed studies in patients without cystic fibrosis are not in
accordance with the previously reported data regarding the
incidence of polymyxin-induced neurotoxicity [11,12,38]. No
episodes of neuromuscular blockade or apnea induced by pol-
ymyxins have been reported in the literature over the past 15
years or more.
Mechanisms
The interaction of polymyxins with neurons, which have a high
lipid content, has been associated with the occurrence of sev-
eral neurotoxic events. In addition, the probability of develop-
ment of neurotoxicity has been directly associated with the
concentration of the active form of polymyxins in the blood
[14]. Neuromuscular blockade induced by polymyxins has
been attributed to a presenaptic action of polymyxins that
interferes with the receptor site and blocks the release of ace-
tylcholine to the synaptic gap [33,52]. Other investigators
have suggested a biphasic mechanism to explain this neuro-
toxic event; a short phase of competitive blockade between
acetylcholine and polymyxins is followed by a prolonged phase
of depolarization associated with calcium depletion
[51,53,54]. Neurotoxicity resulting from the use of polymyxins
is also considered to be dose-dependent.
Clinical manifestations
The reported neurological toxicity is associated with dizziness,
generalized or not muscle weakness, facial and peripheral par-
esthesia, partial deafness, visual disturbances, vertigo, confu-
sion, hallucinations, seizures, ataxia, and neuromuscular
blockade. The last of these usually produces a myasthenia-like
clinical syndrome, as well as respiratory failure or apnea due to
respiratory muscle paralysis [33]. Paresthesias appear to be
usually benign, and their mechanism seems to be unrelated to
the interference with nerve transmission. An old study that
assessed the safety of intramuscularly administered colistimet-
hate sodium during 317 courses revealed that neurological
adverse effects were manifested during the first four days of
therapy in 83% of the patients who experienced neurotoxic
events [4].
Risk factors
Risk factors that may potentially trigger the development of
neurotoxicity include hypoxia and the co-administration of pol-
ymyxins with muscle-relaxants, narcotics, sedatives, anes-
thetic drugs, or corticosteroids [22,55]. A patient's gender
may influence the likelihood of development of adverse effects.
Specifically, neurotoxicity seems to be more common in
women, although nephrotoxicity seems to be gender-inde-
pendent [4]. Patients with impaired renal function or myasthe-
nia gravis are at higher risk of developing neuromuscular
blockade and respiratory paralysis [47].Available online http://ccforum.com/content/10/1/R27
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Treatment
Mild neurological manifestations of polymyxins usually subside
after prompt cessation of the drugs. In the presence of neu-
romuscular blockade, immediate discontinuation of polymyxins
and other neurotoxic agents is also the first-line approach. Fur-
ther management consists of mechanical respiratory support
if apnea has been developed. The intravenous administration
of calcium and cholinesterase inhibitors, such as neostigmine
and edrophonium, has led to conflicting results [33,48].
Hemodialysis is indicated only in patients with co-existing
acute renal failure.
Other adverse events
Incidence
In studies published in the old literature, the reported inci-
dence of allergic reactions related to colistimethate sodium
use was approximately 2% [4]. Mild itching that did not require
discontinuation of the drug was reported by approximately
22% of the patients receiving colistimethate sodium intrave-
nously [27]. In addition, a few patients with episodes of rash
were also reported [20,56]. In the recent literature, a few
patients with episodes of contact dermatitis (eczema and ery-
thematous eruption) have been reported in connection with
topical use of colistin sulfate and ophthalmic administration of
colistimethate sodium [57,58].
Mechanisms
Several milder adverse reactions, including pruritus, dermati-
tis, and drug fever, probably represent the result of the irritative
effects of the active forms of polymyxins [14] and their hista-
mine-releasing action, especially polymyxin B.
Clinical manifestations
Pruritus, contact dermatitis, macular rash or urticaria, ototoxic-
ity, drug fever, and gastrointestinal disturbances may develop,
although rarely, during treatment with polymyxins [26,57,59].
After intramuscular administration, pain may occur at the injec-
tion site [24]. Moreover, the development of pseudomembra-
nous colitis represents a rare side effect of polymyxins.
Intraventricular or intrathecal administration of polymyxins,
especially in high doses, may lead to convulsions and signs of
meningismus. During repeated ophthalmic application of poly-
myxin, low-grade conjunctivitis may develop [14].
An old case report suggested that the administration of colis-
timethate sodium intramuscularly in a patient with Gram-nega-
tive rod bacteremia was possibly associated with
hepatotoxicity because an observed rise in serum glutamic
oxaloacetic transaminase levels returned to normal after the
drug was discontinued; in addition, post-mortem histological
examination of the liver revealed non-specific changes (focal
vacuolization of hepatic cells in the centrilobular fields with
areas of focal necrosis), which were interpreted as drug-
induced toxicity [19]. However, no other cases of liver toxicity
have been reported in experimental or clinical studies on the
use of polymyxins [38,60].
Risk factors
Patients with known allergy to bacitracin are also at higher risk
of developing hypersensitivity reactions with the use of poly-
myxins, as cross-reaction between bacitracin and polymyxins
exists [58].
Treatment
In most instances, withdrawal of polymyxins in combination
with appropriate supportive treatment is adequate for the
treatment of such adverse effects.
Adverse events related to aerosolised colistin
Treatment with aerosolized colistin may be complicated by
sore throat, cough, bronchoconstriction, and chest tightness.
The nature of bronchoconstriction that develops during nebuli-
zation of polymyxins has been proposed to be associated with
several mechanisms. Among them are direct chemical stimula-
tion, the liberation of histamine, allergy in the airway, irritation
from chemicals or from the foam that is produced during neb-
ulization, and hyperosmolarity in the airway [61]. Nebulized
polymyxins can cause bronchoconstriction even in patients
with no history of asthma or atopy, although if these conditions
exist the risk is greater [61]. Bronchoconstriction usually
requires discontinuation of the medication, the administration
of bronchodilators and supplemental oxygen.
Prevention of adverse events
Early and correct adjustment of the dose of polymyxins in the
presence of impaired renal function, frequent urinalyses and
serum urea or creatinine measurements, close daily monitoring
of urinary output and of neurological status, and the avoidance
of concurrent administration of other agents with known neph-
rotoxicity or neurotoxicity may help prevent the development of
adverse effects. Bronchoconstriction usually responds to
treatment with bronchodilators; thus, pre-treatment of patients
receiving inhaled colistimethate sodium with these medica-
tions could prevent the occurrence of this adverse event [61].
Recommendations regarding the dosage of polymyxins differ
between various manufacturers. Colistin manufactured in the
United States contains colistimethate sodium equivalent to
150 mg colistin base activity in each vial. The recommended
dosage is 2.5 to 5 mg/kg per day, divided into 2 to 4 equal
doses in adult patients with normal kidney function [62]. Man-
ufacturers in the United Kingdom recommend a dosage of 4 to
6 mg/kg (50,000 to 75,000 IU/kg) intravenous colistimethate
sodium per day, in 3 divided doses for adults and children with
body-weight ≤ 60 kg, and 80 to 160 mg (1 to 2 million IU)
every 8 hours for body-weight >60 kg [63].
The recommended dosage for intravenous polymyxin B sul-
phate is 1.5 mg to 2.5 mg/kg/day (15,000 IU to 25,000 IU/kg/C
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Table 2
Recent studies (from 1995 to 2005) reporting data on polymyxin-induced toxicity in patients without cystic fibrosis
Year [ref] Setting Medication 
used
Number. of 
patients
Demographics Dosage of colistin/duration Definition of nephrotoxicity Nephrotoxicity Neurotoxicity Other toxicities
1 1995 [57] Department of 
dermatology
Colistin sulfate 
(ointment/
topically)
1 45 year old 50,000 IU for 10 days Edematous eczema
2 1998 [58] Department of 
dermatology
Colistimethate 
sodium 
(ophthalmic 
solution)
1 4 year old male 
with bilateral 
ocular 
prosthesis
After 3 weeks he 
developed itchy 
erythematous eruptions on 
both periorbital areas
3 1999 [72] Neurosurgical 
wards
Colistimethate 
sodium 
(intraventricular)
2 16 year old male 
and 34 year old 
female
Case 1: 5 mg (62,500 IU) 
q12h for 19 days Case 2: 5 mg 
(62,500 IU) q12h for 5 days 
then 10 mg (125,000 IU) q12h 
for 12 days
No adverse reactions
4 1999 [8] ICU (52%), 
transplant unit 
(13%), surgical 
and medical 
wards (35%)
Colistimethate 
sodium (IV)
59 (60 cases) Mean age: 42.1 
years. Mean (± 
SD) APACHE II: 
13.1 (± 7.0)
Mean duration: 12.6 d (2 to 34 
d). Mean daily dose: 152.8 mg 
(approximately 2 MIU) (60–
300 mg)
22 pts (37%; 11/41 with normal 
baseline renal function had 
worsening during treatment (mean 
increase in serum creatinine 0.9 ± 
0.6 mg/dl) and 11/19 with abnormal 
baseline renal function had 
worsening during treatment (mean 
increase in serum creatinine 1.5 ± 
1.4 mg/dl)). Nephrotoxicity did not 
cause discontinuation
No neuromuscular disorders
5 2000 [73] Medical wards Colistimethate 
sodium 
(aerosol)
3 67 year old 
male, 45 year 
old male, 59 
year old male
150 mg (2 MIU) q12h for 13 
days, 100 mg (approximately 
1.5 MIU) q12h for 14 days, 
150 mg (2 MIU) q12h for 11 
days
No nephrotoxicity No hematological toxicity
6 2002 [74] Neurosurgical 
wards
Colistimethate 
sodium (IV)
1 14 year old male 1 MIU q6h for 30 days No adverse reactions
7 2003 [10] Abdominal 
organ 
transplantation 
ICU
Colistimethate 
sodium (IV)
23 (20 had 
received organ 
transplantation, 3 
abdominal 
surgery)
Mean age: 52 
years
Mean duration: 17 days (7 to 
36 days)
Renal failure was defined by a 
requirement either for intermittent 
hemodialysis or for continuous 
venous hemofiltration
1/2 pts developed renal failure 
requiring artificial kidney support 
(the other 21 pts were already 
receiving artificial kidney support)
1 pt diffuse muscular 
weakness (resolved after 
discontinuation)
8 2003 [11] ICU Colistimethate 
sodium (IV)
24 with sepsis, 
26 courses of 
colistin
Mean age: 44.3 
years. Mean 
APACHE II: 
20.6
Mean duration: 13.5 days (4 to 
24 days). Dosage: 3 MIU q8h
Renal failure was defined as an 
increase in serum creatinine >1 
mg/dl during treatment
3 pts (14.3%). Only 1 pt required 
continuous venovenous 
hemodiafiltration
No clinically apparent 
neuromuscular transmission 
blockade
9 2003 [36] Tertiary care 
hospital
Polymyxin B 
(parenterally)
60 receiving 
polymyxin B
Mean age: 61 
years
Mean duration: 13.5 days (1 to 
56 days). Mean daily dose: 1.1 
MIU
Renal failure was defined as 
doubling of serum creatinine value 
of ≥ 2.0 mg/dl
7/50 pts (14%)A
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10 2003 [74] ICU Colistimethate 
sodium (IV)
35 (21 received 
colistin (CO 
group) and 14 
imipenem (IM 
group))
Mean age: CO 
group 56.9 
years, IM group 
64.5 years. 
Mean APACHE 
II: CO group 
19.6, IM group 
20.5
CO group: mean duration 14,7 
days (10 to 21 days). Dosage: 
2.5 to 5 mg/kg/day
In patients with normal renal 
function (creatinine <1.2), renal 
failure was defined as creatinine 
value >2 mg/dl, as a reduction of 
creatinine clearance of 50% 
relative to antibiotic initiation, or 
need for renal replacement 
therapy. In patients with normal 
renal function, renal failure was 
defined as increase of 50% of the 
baseline creatinine level, as a 
reduction of creatinine clearance 
of 50% relative to antibiotic 
initiation, or need for renal 
replacement therapy
5/21 pts (24%; CO group), 6/14 
pts (42%; IM group)
11 2004 [75] ICU Colistimethate 
sodium (IV)
1 41 year old male 2 MIU/day continuous infusion No adverse reactions
12 2004 [76] ICU Colistimethate 
sodium (IV)
1 48 year old male 9 MIU/day (2.5 mg/kg/day) for 
15 days
No adverse reactions
13 2004 [37] Tertiary care 
hospital, ICU 
(92%)
Polymyxin B (IV) 25 (29 courses: 
21 IV, 6 aerosol, 
2 combination)
Mean age: 55 
years. Mean 
APACHE II: 21
Loading dose on day 1 with 2.5 
to 3 mg/kg IV polymyxin B. 
Aerosolized: approximately 2.5 
mg/kg/day (approximately 1.75 
MIU). Mean duration: 19 d (2 to 
57 d)
Nephrotoxicity was defined as the 
doubling of serum creatinine 
during therapy
3/29 courses (10%) 2/29 courses (7%) onset of 
seizures and neuromuscular 
weakness possibly related to 
polymyxin B
14 2005 [12] ICU Colistimethate 
sodium (IV)
43 Mean age: 56.5 
years. APACHE 
II: 25.8 ± 3.7
3 MIU q8h Acute renal failure was defined as 
a rise of ≥ 2 mg/dl in serum 
creatinine level in patients with 
previously normal renal function. 
In patients with a history of renal 
insufficiency, acute on chronic 
renal failure was defined as at 
least doubling of the baseline 
serum creatinine level (defined as 
the creatinine level at the initiation 
of colistin treatment)
8/43 pts (18.6%; 3/35 pts with 
normal renal function (8.6%) and 5/
8 pts with chronic renal failure 
(62.5%))
No paresthesias, vertigo, 
muscle weakness, or apnea 
were observed
15 2005 [77] ICU (84%), 
medical (11%), 
surgical (5%)
Colistimethate 
sodium (aerosol, 
IV, IM, 
intrathecal)
80 (85 courses: 
71 aerosol, 12 IV 
or IM, 2 
intrathecal)
Mean age: 57 ± 
15 years
Mean duration of aerosol: 12 ± 
8 d. Mean duration of IV or IM: 
11 ± 6 d. Mean duration of 
intrathecal: 8 d and 10 d
Nephrotoxicity was defined as a 
serum creatinine increase of 50% 
or 1 mg/dl with respect to the 
baseline level during treatment
12 courses of IV or IM were 
recorded. Mean ± SD baseline 
serum creatinine: 1.25 ± 0.79 mg/
dl. Mean ± SD final serum 
creatinine: 1.20 ± 0.64 mg/dl. Mean 
± SD baseline BUN: 8.95 ± 8.96 
µmol/l. Mean ± SD final BUN: 8.39 
± 8.06 µmol/l
16 2005 [38] Mainly ICU pts Colistimethate 
sodium (IV)
17 (19 courses) Median age: 51 
years. Median 
APACHE II: 14
Mean ± SD duration: 43.4 ± 
14.6 days. Mean ± SD daily 
dose: 4.4 MIU (352 mg) ± 2.1 
MIU (168 mg)
Renal failure was defined as an 
increase more than 50% of the 
baseline creatinine level to a value 
higher than 1.3 mg/dl or as a 
decline in renal function requiring 
renal replacement therapy
Median baseline serum creatinine: 
0.6 mg/dl. Slight increase of the 
median of values of creatinine at the 
end by 0.1 mg/dl. Median baseline 
BUN: 42 mg/dl. Median final BUN: 
41 mg/dl. 1 pt had an increase of 
more than 50% of the baseline 
creatinine level to a value higher 
than 1.3 mg/dl at the end of colistin 
treatment
No apnea or other evidence 
of neuromuscular blockade. 
1 pt polyneuropathy 
(improved after the end of 
colistin treatment)
No hepatobiliary toxicity
Table 2 (Continued)
Recent studies (from 1995 to 2005) reporting data on polymyxin-induced toxicity in patients without cystic fibrosisC
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17 2005 [35] ICU (80%), 
medical and 
surgical wards 
(20%)
Colistimethate 
sodium (IV)
50 (54 episodes) Mean age: 59.2 
years. Mean 
APACHE II: 
16.1
Mean duration: 21.5 days. 
Mean daily dose: 4.5 MIU
Renal failure was defined as an 
increase more than 50% of the 
baseline creatinine level to a value 
higher than 1.3 mg/dl or as a 
decline in renal function requiring 
renal replacement therapy
4/50 pts (8%) 1 pt polyneuropathy (not 
confirmed) resolved without 
discontinuation
18 2005 [78] ICU Colistimethate 
sodium 
(aerosol)
8 Mean age: 59.6 
years. Mean 
APACHE II: 
14.6
Dosage (range): 1.5 to 6 MIU/
day. Duration (mean): 10.5 
days
Worsening of renal function: 1 pt No neurotoxicity
19 2005 [79] ICU Colistimethate 
sodium (IV)
1 57 year old male 250 mg q6h for 4 days Acute renal failure (on the 4th day of 
colistin therapy)
20 2005 [80] Neurosurgical 
wards
Colistimethate 
sodium 
(intraventricular)
1 23 year old 
female
125,000 IU q12h for 3 weeks No adverse reactions
21 2005 [81] ICU Colistimethate 
sodium (IV)
55 Mean age: 40 ± 
16 years. Mean 
APACHE II: 21 
± 7
Duration (mean): 13 ± 5 days Renal failure was defined as a 
serum creatinine value of 2 mg/dl 
or higher, as a reduction in 
creatinine clearance of 50% 
compared to therapy initiation, or 
as a decline in renal function that 
prompted renal replacement 
therapy
No adverse reactions. Mean 
creatinine levels before treatment: 
2.3 ± 0.5 mg/dl. Mean creatinine 
levels after treatment: 2.5 ± 0.6 mg/
dl
22 2005 [82] ICU Colistin (IV) 1 35 year old male 6 MIU/day for 12 days, 3 days, 
and 1 day
Acute renal failure occurred at the 
2nd and 3rd introduction of colistin. 
Renal function returned to normal 
values within 3 and 5 days after 
colistin withdrawal
23 2005 [83] ICU Colistimethate 
sodium (IV)
14 Mean age: 49 
years
Mean dose: 6 MIU/day. Mean 
duration: 12 days
1 pt experienced deterioration of 
renal function (serum creatinine up 
to 2.8 mg/dl)
24 2005 [84] ICU, medical 
wards
Colistimethate 
sodium 
(aerosol)
21 Mean age: 60.6 
± 15 years. 
Mean APACHE 
II: 23.1 ± 9.1
19 pts received 2 MIU/day, 1 
pt 3 MIU/day, and another pt 4 
MIU/day. Median duration: 14 
days
Renal failure was defined as a 
decrease in the estimated 
creatinine clearance rate of 50%, 
compared with the rate at the 
start of therapy, or a decline in 
renal function that necessitated 
renal replacement therapy
No episodes of acute renal failure No symptoms of 
neurotoxicity
1 pt experienced 
bronchospasm that 
resolved on 
discontinuation of colistin 
therapy
BUN, blood urea nitrogen; ICU, intensive care unit; IM, intramuscularly; IV, intravenously; MIU, million international units; Pt(s), patient(s); ref, reference; SD, standard deviation.
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day), divided into 2 equal doses for adults and children older
than 2 years with normal renal function; 1 mg of polymyxin B is
equal to 10,000 IU. Infants with normal renal function may
receive up to 4 mg/kg/day (40,000 IU/kg/day) in cases of life-
threatening infections [64].
Overdoses
Overdoses with polymyxins, mainly with colistimethate
sodium, have been reported several times in the old literature.
Although, one case of a three year old child who received intra-
muscularly 450 mg (approximately 5.5 million IU) of colistimet-
hate sodium reported no adverse effects, the majority of cases
with polymyxin overdose resulted in acute renal failure and var-
ious manifestations of neurotoxicity, including neuromuscular
blockade and apnea [3,31,33,34]. It should be emphasized
that cases of polymyxin overdose with fatal consequences are
scarce [29]. There is no antidote for polymyxin overdose. Man-
agement requires early cessation of the medication and appro-
priate supportive treatment. In the presence of established
acute renal failure, haemodialysis and peritoneal dialysis can
only manage renal complications, since they have little influ-
ence on the elimination of polymyxins, as discussed above. If
apnea occurs, mechanical ventilation support is needed.
Drug interactions
The concurrent use of polymyxins with curariform muscle relax-
ants and other neurotoxic drugs such as ether, tubocurarine,
succinylcholine, gallamine, decamethonium, and sodium cit-
rate must be avoided, since these agents may trigger the
development of neuromuscular blockade [55]. Co-administra-
tion of sodium cephalothin and polymyxins may enhance the
development of neurotoxicity, so this combination of antimicro-
bial medication should also be avoided [4]. In addition, antimi-
crobial agents with known neurotoxic effect, such as
aminoglycosides, should generally be avoided or given with
great caution in patients who receive polymyxins. In such
instances, close monitoring of the patients receiving these
antibiotics is mandatory. Experimental studies showed that
application of polymyxins in combination with glutamic acid to
a peripheral nerve could cause transgaglionic degenerative
atrophy [65].
Conclusion
The data from the recent literature suggest that the incidence
of toxicity resulting from the use of polymyxins is less frequent
and severe compared to what has been previously reported.
Possible explanations for the observed discrepancy include
the fact that the available formulation of colistimethate sodium
for intramuscular administration was used intravenously in the
old studies until a new formulation was prepared. In addition,
the intramuscular formulation also contained dibucaine hydro-
chloride, which could potentiate the neurotoxic effect of colis-
timethate sodium. It should be highlighted that the dosages of
polymyxins used in most of the studies published in the old lit-
erature were considerably higher compared to the recom-
mended dosages administered nowadays. In fact, several
reported cases of polymyxin-induced toxicity were associated
with overdose. Thus, this may account for the observed differ-
ence in the incidence of polymyxin-induced toxicity noted
between the old and recently published studies. A major limi-
tation in the interpretation of polymyxin-induced nephrotoxicity
and neurotoxicity in the intensive care unit setting, however, is
the frequent existence of multiple organ failure, septic shock,
and mechanical ventilation support. These conditions may
considerably influence the assessment of polymyxin-induced
toxicity. Dosage adjustment of polymyxins in the presence of
impaired renal function and prompt discontinuation of poly-
myxins after development of early signs of their toxicity were
not always performed in a timely fashion. Furthermore, the
already reported experience regarding the toxicity of polymyx-
ins in the old literature has led to more correct use of these
antibiotics by physicians nowadays. In addition, the avoidance
of co-administration of potential nephrotoxic and/or neurotoxic
agents with polymyxins, as well as the development of critical
care supplies, may also explain the observed differences. In
the coming years further research is needed to assess the
safety profile of polymyxins, clarify several aspects of their tox-
icity, and investigate the benefits of different dosing regimens,
including the administration of these antibiotics in fewer daily
doses.
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